Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Alfimeprase in Acute Ischemic Stroke (CARNEROS-1)
NCT00499902Phase 2Terminated
- Sponsor
- Oruka Therapeutics
- Start
- Jun 2007
- Primary completion
- May 2008
- Modality
- Therapeutic Enzymes
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of alfimeprase in acute ischemic stroke (AIS) (3 arms), sponsored by Oruka Therapeutics. Primary endpoints: Symptomatic Intracerebral Hemorrhage at 24 hours and Recanalization of Primary Arterial Occlusive Lesion. Started Jun 2007; status: terminated.
02
Drugs
alfimeprase
03
Conditions
acute ischemic stroke (AIS)
Beyond the preview
Go deeper on NCT00499902.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00499902.